Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT03873064
Recruiting Observational

Body Mass Index (BMI) and Quality of Life (QoL) in Cancer Patients

NCT03873064 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Rome Tor Vergata
Phase
Observational
Started
2019-01-15
Last updated
2026-09-23

Condition(s) studied

Neoplasm MalignantBody WeightQuality of Life

Study summary

BMI is a simple and widely recorded variable that may capture obesity or cachexia in cancer patients. How BMI is associated to health-related quality of life (HR-QoL) in such patients is poorly investigated.

High BMI may be associated to obesity, an increased burden of comorbidity, reduced physical activity and, in some settings, to more aggressive oncological disease. On the other hand, low BMI may reflect enhanced weight loss, cachectic syndrome, higher tumor burden and adverse prognostic features which all deteriorate quality of life. The aim of the present study is to evaluate the association of BMI and HR-QoL as measured by the EORTC-QLQ-C30 or the EQ-5D-5L questionnaire in several cancer settings (such as localized vs metastatic or distinct primary tumors).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Histologically confirmed diagnosis of solid tumor 2. Age \>18 years 3. Signed informed consent 4. Life expectancy \> 12 weeks Exclusion Criteria: 1. Inability to fill out the questionnaires. 2. Absence of a certain diagnosis of solid tumor (e.g. subjects on screening programs) 3. Diagnosis of second malignancies that might bias results interpretation

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tor Vergata University Hospital Rome Italy Recruiting

More University of Rome Tor Vergata trials in Italy

Evaluation of Functional and Nutritional Parameters in Fit Acute Leukemia Patients Recruiting
Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer Recruiting
Jigsaw Cooperative Learning for Pediatric Pain Education in Undergraduate Nursing Students Starting soon
New Stereophotogrammetry System to Capture Complete-arch Impression Recruiting
Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT Recruiting

Other trials for the same condition

Dietary Quality and Nutritional Adequacy Among Vegetarians Attending the European Institute of Oncology Recruiting
intErnet-based iNterventions FOR Cardiac arrEst suRvivors Recruiting
Idiopathic Generalized Epilepsy Cognitive and Emotional Profile Recruiting
Toxicity and Outcome of Whole Breast Hypofractionated Radiotherapy: a Single Institution Experience Active, not recruiting
Pain ASsessment in CAncer Patients by Machine LEarning (PASCALE) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03873064 on ClinicalTrials.gov ↗ ← All trials in Italy